TABLE 2.

Patient adherence^* to infliximab (IFX) induction therapy and characteristics of early and delayed IFX induction infusions in 140 inflammatory bowel disease patients

Variable
IFX induction, n
Patients receiving IFX induction therapy	140
Total administered IFX induction infusions	412
Adherence to induction IFX
Patients adherent to IFX induction, n (%)	109 (77.9)
Adherent IFX induction infusions per patient, mean ± SD	2.7±0.6
Delayed induction infusions
Patients receiving at least one delayed IFX infusion, n (%)	65 (46.4)
Late infusions per patient, mean ± SD	0.5±0.6
Late days per infusion, mean ± SD	1.5±1.8
Cumulative late days per patient, mean ± SD	2.1±4.1
Early induction infusions
Patients receiving at least one early IFX infusion, n (%)	67 (47.9)
Early infusions per patient, mean ± SD	0.5±0.6
Early days per infusion, mean ± SD	1.2±1.6
Cumulative early days per patient, mean ± SD	1.1±2.8

^*Defined as receiving >80% of induction infusions within 72 h of the regularly scheduled date of infusion at weeks 0, 2 and 6